Skip to main content

MHRAs yellow card scheme

This content has been automatically generated from the original PDF and some formatting may have been lost. Let us know if you find any major problems.

Text in this format is not official and should not be relied upon to extract citations or propose amendments. Please see the PDF for the official version of the document.

WQ.456/2021

WRITTEN QUESTION TO THE MINISTER FOR HEALTH AND SOCIAL SERVICES BY DEPUTY J.M. MAÇON OF ST. SAVIOUR

QUESTION SUBMITTED ON MONDAY 15TH NOVEMBER 2021

ANSWER TO BE TABLED ON MONDAY 22ND NOVEMBER 2021

Question

Will the Minister state whether the Department is able to analyse local trends in adverse drug reactions (A.D.R.s) to the Covid-19 vaccine by extracting Jersey-specific data from the Medicines and Healthcare Products Regulatory Agency's (M.H.R.A.) Yellow Card Scheme datasets; and if not, why not?

Answer

The system for collating reported events that may be related to a drug or vaccine is the yellow card system as discussed in response to WQ457/2021. This permits for a large data base and expert and credible analysis. As stated, that data applies to all vaccine recipients in the UK and Crown Dependencies.